Ipsen

  • Français
Symbol Last Change
IPN.PA 23.16 € (-0.66 % )
powered by Euronext©
  • The Group
    • Profile & Key figures
      • Message from the Chairman
      • Group history
    • R & D
      • R & D Homepage
      • Neurology
      • Endocrinology
      • Oncology
      • Primary care
    • Medicines
    • Governance
      • Board of directors
      • Executive committee
      • Board committees
      • Compensation of corporate officers
    • Business Development & Alliance Management
    • Ipsen worldwide
  • Targeted diseases
    • Neurology
    • Endocrinology
    • Oncology
    • Hematology
    • Primary care
  • Commitments
    • Vision, mission and values
    • Environment, health and safety
    • Ethics and compliance
    • Support to Patient Organizations
    • Solidarity
  • Fondation IPSEN
    • La Fondation Ipsen at a glance
    • Colloques, prizes, publications
      • Neurosciences
      • Alzheimer’s disease
      • Endocrinology
      • Cancer science
      • Longevity
      • Vascular
    • Partnerships
      • Salk Institute - Nature
      • Cell Press - Massachusetts General Hospital
      • Nature Publishing Group

Press releases

  • 27 January 2012 - Paris (France)
    Ipsen acknowledges Tanakan® delisting in France
    application/pdf icon
    Download
  • 24 January 2012 - Paris (France)
    Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
    application/pdf icon
    Download
  • 23 January 2012 - Paris (France)
    Fifth meeting in the “Biological Complexity” series jointly organised by the Fondation Ipsen and the Salk Institute for...
    application/pdf icon
    Download

All press releases

News

29 February 2012
Full year 2011 results
Lire la suite

All news

  • Go to

    PrintPrint
    • Press room
    • Investor relations
    • Careers

    YOUR SERVICES

    • Publications
    • Email alert
    • Follow Ipsen on Facebook Twitter Linked in
© Ipsen 2010
  • Legal disclaimer
  • Site Map
  • Contact
  • Email alert
  • RSS
  • Ipsen worldwide
  • IPSEN related sites

Ipsen Group website.